Immuno oncology News and Research

RSS

Stand Up To Cancer announces new effort to achieve health equity for underserved lung cancer patients

Stand Up To Cancer today announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts aimed at achieving health equity for underserved lung cancer patients, including Black people and people living in rural communities.

16 Jul 2020

Ashion's GEM ExTra assay receives Medicare coverage

Ashion Analytics LLC announced today that Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostic Services Program (MolDX), has awarded coverage to its proprietary cancer profiling test, GEM ExTra®, one of the nation's most comprehensive genomic cancer analysis tests.

15 Jul 2020

MD Anderson and Sanofi collaborate to accelerate development of innovative cancer therapies

The University of Texas MD Anderson Cancer Center and Sanofi today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune therapies, for patients with cancer.

14 Jul 2020

Immunicom and Sheba Medical Center initiate clinical trial to evaluate novel cancer treatment

Sheba Medical Center at Tel HaShomer and Immunicom, Inc. are initiating a ground-breaking clinical trial to evaluate the clinical effectiveness of the Immunicom LW-02 plasma filtration device as a monotherapy and in combination with an anti-PD-1 immune checkpoint inhibitor.

9 Jul 2020

PRMT5 inhibitors can help treat advanced melanoma

Scientists at Sanford Burnham Prebys Medical Discovery Institute have demonstrated the therapeutic potential of PRMT5 inhibitors to sensitize unresponsive melanoma to immune checkpoint therapy.

9 Jul 2020

BIA Separations launches novel PrimaS ligand technology to facilitate development of advanced therapies

BIA Separations, a leading bio-chromatography development and manufacturing company, today announced the introduction of its novel PrimaS ligand technology.

17 Jun 2020

Texas Heart Institute and 7 Hills Pharma receive $1.9 million to improve stem cell transplants

The Texas Heart Institute and 7 Hills Pharma received a $1.9 million, Phase II STTR (R42) grant from the National Heart Lung Blood Institute to advance further their lead product 7HP349, a novel integrin activator, to define the optimal dosing schedule for cord blood transplant along with a focus on development and production of a formulation that meets safety standards for filing an IND application with the FDA.

12 Jun 2020

Promega announces CE marking for OncoMate MSI Dx Analysis System in Europe

Promega Corporation today announced CE marking for the OncoMate MSI Dx Analysis System as a new in vitro diagnostic medical device in Europe.

From Promega Corporation 10 Jun 2020

Immuno-oncology may accelerate the development of treatments for COVID-19

Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.

10 Jun 2020

Bioinsider presents "Diagnostic Landscape For COVID19” virtual meeting

Bioinsider LLC (Bioinsider) will present the “Diagnostic Landscape for COVID-19” virtual meeting on Thursday, June 18, 2020.

8 Jun 2020

Researchers identify key protein required for optimal immune responses to cancer

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute (OSUCCC - James) has identified a protein within certain immune cells that is required for optimal immune responses to cancer.

2 Jun 2020

Journal publication supports Synlogic’s first clinical immuno-oncology program, SYNB1891

Synlogic, Inc., a clinical-stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Nature Communications of preclinical data supporting its first clinical immuno-oncology program, SYNB1891, which is being evaluated in Phase 1 clinical trial in patients with advanced solid tumors or lymphoma.

2 Jun 2020

Scientists identify factors influencing outcomes in kidney cancer patients treated with immunotherapy

By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, Dana-Farber Cancer Institute scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitor drugs.

30 May 2020

Bioinsider launches COVID-19 virtual meeting series

Bioinsider has opened registration and a call for speaker proposals for its four-part virtual meeting series, Together as One COVID-19 Series.

21 May 2020

Finnish research in cancer immunotherapy receives 10 million euros

Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland's Personalized Health Program.

11 May 2020

Sartorius launches the new Incucyte SX5® for live-cell analysis, offering new possibilities for live-cell analysis experiments

Sartorius, a leading international supplier for the biopharmaceutical industry, today launched the new Incucyte SX5 Live-Cell Analysis System, the latest in the company’s line of live-cell analysis products.

From Sartorius 5 May 2020

New 'Immuno-Engineering to Improve Immunotherapy' Center formed to advance cancer therapy

Harvard University's Wyss Institute of Biologically Inspired Engineering and its collaborating institutions, the Harvard John A. Paulson School of Engineering and Applied Sciences, Dana-Farber Cancer Institute, and Harvard's Department of Stem Cell and Regenerative Biology, announce the formation of a new NIH-funded Immuno-Engineering to Improve Immunotherapy Center.

7 Mar 2020

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.

27 Feb 2020

Isolating Single T-cells of Interest using an Optofluidic Platform

Researchers are in desperate need of single-cell analysis techniques and those that allow the isolation of high-value T-cells for research and development.

From Bruker Cellular Analysis 21 Feb 2020

Determining Microsatellite Instability Status Using Multiplex PCR-Based Methods

Determining microsatellite instability status using multiplex PCR-based methods used to screen for Lynch Syndrome, a dominant hereditary cancer propensity.

From Promega Corporation 24 Jan 2020